← Leaderboards
Andrew Koff
Sloan-Kettering Institute For Cancer Res
$7,486,650
Attributed
$7,850,516
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $762.4K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,850,516 · 4
By mechanism
R01$6,283,945 · 3
P50$1,566,571 · 1
Top collaborators
- William D. Tap1 shared
Most similar at Sloan-Kettering Institute For Cancer Res
Same institution · by research overlap
- Carlos Cordon-Cardo$7,210,529
- William Pao$4,438,803
- Marilyn D Resh$12,092,125
- Scott Keeney$13,639,540
- Eric C Holland$32,588,073
Others in their field
Top investigators on “Cyclins”
- Piotr Sicinski · Dana-Farber Cancer Inst$42,699,610
- J. Alan Diehl · University Of Nebraska Medical Center$21,437,568
- Richard G Pestell · Yeshiva University$16,269,311
- Steven I Reed · Scripps Research Institute$16,177,190
- Bruce E Clurman · Fred Hutchinson Cancer Research Center$15,606,607
- David Owen Morgan · University Of California San Francisco$15,595,703
Research focus
CyclinsCell LineCellsBiochemicalInsightCell CycleAffectTumorRegulationSamplingMolecularPhosphorylationTumor ProgressionMutationProteinsNeoplastic CellCollectionCyclin Dependent KinaseInhibitor/AntagonistLaboratory MouseCell Cycle ProteinsMessenger RnaEnzyme InhibitorsMalignant Neoplasms
Grant awards (21)
Improving CDK4/6 inhibition therapy for patients with liposarcoma by understanding resistance$727,732
R01 · FY2025 · CA
CDK4 Inhibitor Therapy: Identification of Biomarkers and Combination Therapies for Liposarcoma$310,610
P50 · FY2022 · CA · contact PI
CDK4 Inhibitor Therapy: Identification of Biomarkers and Combination Therapies for Liposarcoma$310,609
P50 · FY2021 · CA · contact PI
CDK4 Inhibitor Therapy: Identification of Biomarkers and Combination Therapies for Liposarcoma$314,986
P50 · FY2020 · CA · contact PI
CDK4 Inhibitor Therapy: Identification of Biomarkers and Combination Therapies for Liposarcoma$303,751
P50 · FY2019 · CA · contact PI
CDK4 Inhibitor Therapy: Identification of Biomarkers and Combination Therapies for Liposarcoma$326,615
P50 · FY2018 · CA · contact PI
CDK inhibitors in tumor progression$404,602
R01 · FY2011 · CA · contact PI
CDK inhibitors in tumor progression$420,049
R01 · FY2010 · CA · contact PI
CDK inhibitors in tumor progression$414,775
R01 · FY2009 · CA · contact PI
CDK inhibitors in tumor progression$347,600
R01 · FY2009 · CA · contact PI
CDK inhibitors in tumor progression$405,656
R01 · FY2008 · CA · contact PI
CDK inhibitors in tumor progression$406,170
R01 · FY2007 · CA · contact PI
P27KIP1 EXPRESSION, A PROGNOSTIC INDICATOR==BUT WHY?$351,731
R01 · FY2005 · CA
P27KIP1 EXPRESSION, A PROGNOSTIC INDICATOR==BUT WHY?$351,731
R01 · FY2004 · CA
REGULATION OF P27 AND ITS ROLE IN G1 PROGRESSION$371,464
R01 · FY2003 · GM
P27KIP1 EXPRESSION, A PROGNOSTIC INDICATOR==BUT WHY?$351,731
R01 · FY2003 · CA
REGULATION OF P27 AND ITS ROLE IN G1 PROGRESSION$360,741
R01 · FY2002 · GM
P27KIP1 EXPRESSION, A PROGNOSTIC INDICATOR==BUT WHY?$351,731
R01 · FY2002 · CA
P27KIP1 EXPRESSION, A PROGNOSTIC INDICATOR==BUT WHY?$351,731
R01 · FY2001 · CA
REGULATION OF P27 AND ITS ROLE IN G1 PROGRESSION$350,328
R01 · FY2001 · GM
REGULATION OF P27 AND ITS ROLE IN G1 PROGRESSION$316,173
R01 · FY2000 · GM